Gsa Capital Partners LLP Editas Medicine, Inc. Transaction History
Gsa Capital Partners LLP
- $1.32 Billion
- Q3 2024
A detailed history of Gsa Capital Partners LLP transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 182,725 shares of EDIT stock, worth $221,097. This represents 0.05% of its overall portfolio holdings.
Number of Shares
182,725
Previous 96,705
88.95%
Holding current value
$221,097
Previous $452,000
37.83%
% of portfolio
0.05%
Previous 0.03%
Shares
18 transactions
Others Institutions Holding EDIT
# of Institutions
248Shares Held
57MCall Options Held
410KPut Options Held
394K-
Black Rock Inc. New York, NY7.78MShares$9.42 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.68MShares$8.08 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.9MShares$5.93 Million0.62% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.35MShares$4.05 Million0.01% of portfolio
-
State Street Corp Boston, MA2.46MShares$2.98 Million0.0% of portfolio
About Editas Medicine, Inc.
- Ticker EDIT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,737,200
- Market Cap $83.2M
- Description
- Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...